Welcome to NeuroField – Neurofeedback Evolved
What is NeuroField?
The NeuroField technology incorporates very low intensity,pulsed electromagnetic field (pEMF) stimulation, transcranial direct current and alternating current stimulation (tDCS/tACS), heart rate variability (HRV) and electroencephalography (EEG) all in one biofeedback system.
The NeuroField X3000 is a four channel frequency generator that can generate pEMF frequencies from 0.31-300,000 Hz. The pEMF output ranges from 1-50 microtesla. NeuroField low intensity pEMF is 10,000,000 times weaker than traditional rTMS (transcranial magnetic stimulation) which was approved by the FDA in 2008 for the treatment of depression. The NeuroField X3000 Plus is FDA 510K exempt registered.
The tDCS/tACS is a single channel transcranial stimulation device, capable of generating frequencies from 0.001-1,000 Hz. The maximum output power is limited to 2.5mA, within the NIH maximum recommended for transcranial direct current stimulation.
The NeuroField Q20 EEG is a DC coupled, 19 channel EEG amplifier. The Q20 is sharp, clean EEG that has can used with the X3000 device to measure EEG in between pEMF stimulation utilizing the real time z-score procedure in the NeuroField software platform. The Q20 has also been integrated in the Neuroguide 19 channel LORETA and Surface neurofeedback z-score platform. In this way the Q20 is truely a versatile EEG amplifier that combines pEMF, tDCS/tACS and z-score neurofeedback technologies.
NeuroField has evolved into the first system that measures physiological responses to pEMF or tDCS/tACS through EEG and HRV. Furthermore, NeuroField stimulation therapy uses norm referenced, z-score, data to guide the brain to a regulated, normative state. As a result of these innovations,
Z-score’s are calculated in real time after pEMF or tDCS/tACS stimulation is given to determine which frequency guides the brain to the normative range.
The use of energy to address human ailments has been a source of exploration for centuries beginning with the use of electric eels, to the use of static electricity, to various forms of magnetic therapies that used stones, ore, and the laying of hands to heal those afflicted with various illnesses (Kellaway, 1946; Payne, 1990; Quinn & Strelkauskas, 1993; Quinn, 1984, 1992; Krieger, 1975). In the past 30 years there have been many different types of energy techniques offered as a form of valid therapy. One of these modalities is known as transcranial magnetic stimulation, or TMS.
TMS was originally developed by Anthony Barker at the University of Sheffield in 1985. Barker demonstrated an evoked motor response (thumb movement) by applying an electromagnetic stimulation (EMF of 1-2 Tesla) over the motor cortex of humans (Barker, Jalinous, & Freeston, 1985). As the technology evolved it became possible to give multiple pulses to people which gave rise to repetitive or rTMS. Since that time a great deal of research has been conducted strongly suggesting that rTMS has clinical value for the treatment of depression and other psychiatric conditions (Pascual-Leone et al., 1999; Arns, M., Spronk, D., & Fitzgerald, P. B. (2010); Avery, D. H., Holtzheimer, P. E., Fawaz, W., Russo, J., Neumaier, J., Dunner, D. L., et al.(2006); Brakemeier, E. L., Wilbertz, G., Rodax, S., Danker-Hopfe, H., Zinka, B., Zwanzger, P.,et al. (2008). Furthermore, rTMS has been deemed safe by the FDA and was approved for the treatment of depression in 2008.
rTMS protocols are known as either being high frequency (HF-rTMS, EMF stimulation 5Hz or greater) or low frequency (LF-rTMS, EMF stimulation 1 Hz or less). The EMF frequency and site of stimulation is theorized to have clinical effects that can have either an excitatory or inhibitory impact on neuronal cellular activity. However, due to the high intensity EMF, giving stimulation faster than 20-30 Hz at intensities >1 tesla for long durations can result in the generation of heat which can damage tissue. As a result rTMS protocols are typically given in short pulses with an ‘on’ and ‘off’ time that prevents tissue damage, but limits the frequency range in which the therapy can be given. The safety of rTMS therapy was deemed safe by the FDA in 2008 and approved for the treatment of depression in the United States.
The notion that low intensity electromagnetic stimulation could be of clinical value was one of the driving forces behind the development of the NeuroField technology.
The NeuroField system was initially evaluated by 10 beta testers around the United States. All of which are licensed health care professionals. Dr. Dogris has written well over 50 experimental protocols for the system that have been rated by NeuroField users as having clinical value. The inflammation reduction protocol has been given the highest ratings with more than 30 NeuroField users confirming observed inflammation reduction in their clients. This technology is experimental and is currently being evaluated by licensed health care professionals. The clinical use of NeuroField is for stress reduction and relaxation. NeuroField is not available to the general public and requires a professional license to obtain at this time.